Tekla Life Sciences Stock Working Capital
HQL Stock | USD 14.26 0.13 0.92% |
Tekla Life Sciences fundamentals help investors to digest information that contributes to Tekla Life's financial success or failures. It also enables traders to predict the movement of Tekla Stock. The fundamental analysis module provides a way to measure Tekla Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tekla Life stock.
Last Reported | Projected for Next Year | ||
Change In Working Capital | -60.4 M | -57.4 M |
Tekla | Working Capital |
Tekla Life Sciences Company Working Capital Analysis
Tekla Life's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Tekla Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Tekla Life is extremely important. It helps to project a fair market value of Tekla Stock properly, considering its historical fundamentals such as Working Capital. Since Tekla Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tekla Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tekla Life's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
Tekla Capital Stock
Capital Stock |
|
According to the company's disclosures, Tekla Life Sciences has a Working Capital of 0.0. This is 100.0% lower than that of the Capital Markets sector and 100.0% lower than that of the Financials industry. The working capital for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
All Next | Launch Module |
Tekla Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tekla Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tekla Life's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Tekla Fundamentals
Return On Equity | 0.0128 | ||||
Return On Asset | -0.0032 | ||||
Profit Margin | 1.56 % | ||||
Operating Margin | (0.32) % | ||||
Current Valuation | 370.8 M | ||||
Shares Outstanding | 27.35 M | ||||
Shares Owned By Insiders | 0.01 % | ||||
Shares Owned By Institutions | 35.35 % | ||||
Number Of Shares Shorted | 74.12 K | ||||
Price To Earning | 2.84 X | ||||
Price To Book | 0.88 X | ||||
Price To Sales | 111.02 X | ||||
Revenue | 23.52 M | ||||
Gross Profit | 3.02 M | ||||
EBITDA | 22.35 M | ||||
Net Income | 22.35 M | ||||
Cash And Equivalents | 292.4 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 666.96 K | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 1.34 X | ||||
Book Value Per Share | 16.13 X | ||||
Cash Flow From Operations | (12.8 M) | ||||
Short Ratio | 1.23 X | ||||
Earnings Per Share | 1.34 X | ||||
Beta | 0.71 | ||||
Market Capitalization | 390.02 M | ||||
Total Asset | 402.6 M | ||||
Retained Earnings | (1.48 M) | ||||
Annual Yield | 0.14 % | ||||
Five Year Return | 8.83 % | ||||
Net Asset | 402.6 M | ||||
Last Dividend Paid | 1.3 |
About Tekla Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tekla Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tekla Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tekla Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tekla Life Piotroski F Score and Tekla Life Altman Z Score analysis. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.425 | Dividend Share 1.3 | Earnings Share 1.34 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.07 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.